Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea flag South Korea · Delayed Price · Currency is KRW
80,800
0.00 (0.00%)
Feb 19, 2025, 9:00 AM KST

KRX:185750 Revenue

Chong Kun Dang Pharmaceutical had revenue of 412.76B KRW in the quarter ending September 30, 2024, with 2.27% growth. This brings the company's revenue in the last twelve months to 1.68T, up 7.29% year-over-year. In the year 2023, Chong Kun Dang Pharmaceutical had annual revenue of 1.67T with 12.17% growth.

Revenue (ttm)
1,675.68B
Revenue Growth
+7.29%
P/S Ratio
0.65
Revenue / Employee
736.24M
Employees
2,276
Market Cap
1,073.85B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20231,669.40B181.06B12.17%
Dec 31, 20221,488.34B144.79B10.78%
Dec 31, 20211,343.56B40.55B3.11%
Dec 31, 20201,303.01B223.67B20.72%
Dec 31, 20191,079.34B123.12B12.88%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,364.39B
Celltrion 2,876.25B
Yuhan 2,008.84B
SK Biopharmaceuticals 511.33B
SK bioscience 201.30B
Hanmi Pharm. 1,495.50B
Hanall Biopharma 134.24B
Hanmi Science 1,283.65B
Revenue Rankings